NCT05701423View on ClinicalTrials.gov

A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

TerminatedOBSERVATIONAL
Enrollment

34

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Multiple Sclerosis
Interventions
DRUG

Natalizumab

Administered as specified in the treatment arm.

Trial Locations (1)

40225

Klinik für Neurologie, Universitätsklinikum Düsseldorf, Düsseldorf

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY